NeuroThera Labs initiates Phase IIb trial site in Germany for Tourette treatment candidate SCI-110

• Neurothera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, its cannabinoid-based treatment candidate for adult Tourette syndrome.
• Phase IIb is a randomized, double-blind, placebo-controlled, cross-over study testing daily oral dosing in patients aged 18-65.
• Primary endpoint is change in Yale Global Tic Severity Scale at weeks 12 and 26 versus baseline; safety tracked via adverse-event monitoring.
• Phase IIa results cited an average 21% tic reduction across participants, supporting the move into the larger Phase IIb study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202607150831TNWSWRCACNPR_____1LpMF0p9W) on July 15, 2026, and is solely responsible for the information contained therein.